Scottish NHS patients to access Pfizer’s Ibrance combo in HR+/HER- breast cancer following SMC recommendation

pharmafile | July 11, 2019 | News story | Sales and Marketing Cancer, Scotland, Scottish Medicines Consortium, breast cancer, ibrance, pharma 

Female NHS patients in Scotland will soon be able to access Pfizer’s cyclin-dependent kinase (CDK) 4/6 inhibitor Ibrance (palbociclib) after the Scottish Medicines Consortium chose to recommend the therapy in combination with fulvestrant for the treatment of hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer in patients who have received prior endocrine treatment.

The decision was based on Phase 3 data supporting the efficacy of the combo therapy in the recommended indication; it is thought that around 400 patients in Scotland will be eligible to it.

“We are delighted with today’s news from the SMC. Treating women with palbociclib and fulvestrant has been found to be an important and effective option for those who have already received earlier rounds of hormone therapy and we are pleased that this combination of medicines will now be routinely available in Scotland,” commented Dr Olivia Ashman, Oncology Medical Director at Pfizer UK. “We know that this approval from the SMC will be meaningful for the many patients and families who are affected by this type of advanced breast cancer and we hope the same outcome will be reached by NICE later this year.”

NICE, which assesses the availability of medicines to NHS patients in England and Wales, is currently working through its own appraisal for the therapy, and is expected to reach a decision before the end of the year.

Matt Fellows

Related Content

Geneos Therapeutics shares data from phase 1/2 trial for cancer vaccine

Geneos Therapeutics has announced that it has published positive safety, immunogenicity and efficacy data from …

FDA accepts BLA for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for breast cancer treatment

AstraZeneca and Daiichi Sankyo have announced that their Biologics License Application (BLA) for datopotamab deruxtecan …

Curve Therapeutics’ CSO publishes research on HIF inhibition for cancer treatment

Curve Therapeutics has announced that its chief scientific officer, Professor Ali Tavassoli has published research …

Latest content